Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-surgical MK-2206 in Operable Invasive Breast Cancer
NCT01319539Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2011
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-2206 in breast cancer, sponsored by National Cancer Institute. Started Apr 2011; status: terminated.
02
Drugs
MK-2206
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01319539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01319539.